2024
Impact of Inpatient Percutaneous Coronary Intervention Volume on 30-Day Readmissions After Acute Myocardial Infarction-Cardiogenic Shock
Bansal K, Gupta M, Garg M, Patel N, Truesdell A, Babar Basir M, Rab S, Ahmad T, Kapur N, Desai N, Vallabhajosyula S. Impact of Inpatient Percutaneous Coronary Intervention Volume on 30-Day Readmissions After Acute Myocardial Infarction-Cardiogenic Shock. JACC Heart Failure 2024 PMID: 39243243, DOI: 10.1016/j.jchf.2024.07.014.Peer-Reviewed Original ResearchPercutaneous coronary interventionCardiogenic shockAcute myocardial infarctionAnnual PCI volumesHeart failureAll-causeHigh-volume PCI centersHigh-volume centersAMI-CSNationwide Readmissions DatabaseMedian annual PCI volumesVolume-outcome relationshipAMI-CS admissionsHospital PCI volumePercutaneous coronary intervention volumeVolume centersOrgan dysfunctionPCI centerMultivariable adjustmentHF readmissionSupportive therapyHighest quartilesQ1 hospitalsNoncardiac readmissionComorbidity burden
2020
Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT)
Pareek M, Byrne C, Vaduganathan M, Biering-Sorensen T, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum bicarbonate, intensive blood pressure lowering, and mortality: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2731. DOI: 10.1093/ehjci/ehaa946.2731.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressureSerum bicarbonate levelsBlood pressureBaseline bicarbonateBicarbonate levelsCV causesAntihypertensive treatmentSystolic blood pressure 130End-stage renal diseaseStandard antihypertensive treatmentHigh cardiovascular riskChronic kidney diseaseGlomerular filtration rateRisk of deathStandard blood pressureLow bicarbonate levelsYears of ageMultivariable adjustmentCardiovascular riskSerum bicarbonateRenal diseaseLaboratory variablesPrognostic implicationsIntervention trialsBaseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT)
Byrne C, Pareek M, Biering-Soerensen T, Vaduganathan M, Krogager M, Kragholm K, McCullough M, Desai N, Olsen M, Bhatt D. Baseline and on-treatment serum potassium and mortality in high risk patients: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal 2020, 41: ehaa946.2732. DOI: 10.1093/ehjci/ehaa946.2732.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialIntensive blood pressure loweringBlood pressure loweringSerum potassium levelsIntensive blood pressureSerum potassiumPressure loweringPotassium levelsCV causesMultivariable adjustmentBlood pressureSystolic blood pressure 130End-stage renal diseaseBaseline serum potassiumLong-time mortalityShort-time mortalityStandard antihypertensive treatmentHigh cardiovascular riskHigh-risk patientsGlomerular filtration rateYears of ageSerum potassium measurementsAntihypertensive treatmentCardiovascular riskRenal function